Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 4/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | WRN | Q14191 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4727448 | 1.00 | GRM4 (0.48) | GRM4BLMWRNKMT2AMEN1 | |
| SCHEMBL14259993 | 0.83 | GRM4 (0.49) | GRM4BLMWRNKMT2AMEN1 | |
| SCHEMBL4728352 | 0.80 | MEN1 (0.49) | KMT2AMEN1GAAGFER | |
| SCHEMBL4728350 | 0.80 | MEN1 (0.49) | KMT2AMEN1GAAGFER | |
| SCHEMBL4725734 | 0.80 | ALDH1A1 (0.48) | GRM4BLMWRNKMT2AMEN1 | |
| SCHEMBL4725732 | 0.80 | ALDH1A1 (0.48) | GRM4BLMWRNKMT2AMEN1 | |
| SCHEMBL4727828 | 0.80 | ALDH1A1 (0.47) | GRM4BLMKMT2AMEN1GAA | |
| SCHEMBL4727832 | 0.80 | ALDH1A1 (0.47) | GRM4BLMKMT2AMEN1GAA | |
| SCHEMBL30050843 | 0.78 | GRM4 (0.46) | GRM4BLMWRNAKT1ABCG2 | |
| SCHEMBL4727452 | 0.77 | IDO1 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080146624-A1 | AMIDINES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2008-06-19 | — | — | US | claimed |
| WO-2008036652-A2 | AMIDINES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2008-03-27 | — | — | WO | claimed |
| US-20080146624-A1 | AMIDINES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146624-A1 | AMIDINES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, INMT | GRM4 489/4885BLM 3769/4885WRN 2625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.